Overview of the potency of moxifloxacin ophthalmic solution 0.5% (VIGAMOX®)

Survey of Ophthalmology

Volumn 50, Issue 6 SUPPL. 1, 2005, Pages

  Schlech, Barry A ^a   Alfonso, Eduardo ^b  

^a ALCON RESEARCH LTD   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotic; Breakpoints; Fluoroquinolone in vitro; in vivo; MIC; Moxifloxacin; MPC; Pharmacodynamics; Pharmacokinetic; Potency; Therapeutic index; VIGAMOX

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN;

CLINICAL TRIAL; CONJUNCTIVITIS; DRUG EFFICACY; DRUG POTENCY; EYE INFECTION; HUMAN; KERATITIS; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 27844486699     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.survophthal.2005.05.002     Document Type: Article

References (44)

1. R. Abshire, P. Cockrum, and J. Crider Topical antibacterial therapy for mycobacterial keratitis: potential for surgical prophylaxis and treatment Clin Ther 26 2004 191 196
2. E. Aliprandis, J. Ciralsky, and H. Lai Comparative efficacy of topical moxifloxacin versus ciprofloxacin and vancomycin in the treatment of P. aeruginosa and ciprofloxacin-resistant MRSA keratitis in rabbits Cornea 24 2005 201 205
3. D.R. Andes, and W.A. Craig Pharmacodynamics of fluoroquinolones in experimental models of endocarditis Clin Infect Dis 27 1998 47 50
4. J.M. Andrews Determination of minimum inhibitory concentrations J Antimicrob Chemother 48 Suppl 1 2001 S5 S16
5. J.M. Blondeau Fluoroquinolones: mechanism of action, classification, and development of resistance Surv Ophthalmol 49 Suppl 2 2004 S73 S78
6. J.M. Blondeau, G. Hansen, K. Metzler, and P. Hedlin The role of PK/PD parameters to avoid selection and increasee of resistance: mutant prevention concentration J Chemother 16 Suppl 3 2004 S1 S19
7. J.M. Blondeau, X. Zhao, and G. Hansen Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae Antimicrob Agents Chemother 45 2001 433 438
8. W.A. Craig Choosing an antibiotic on the basis of pharmacodynamics Ear Nose Throat J 77 Suppl 1998 S7 S12
9. W.A. Craig Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men Clin Infect Dis 26 1998 1 12
10. A. Dalhoff Pharmacodynamics of fluoroquinolones J Antimicrob Chemother 43 Suppl B 1999 S51 S59
11. A. Dalhoff, and F.J. Schmitz In vitro antibacterial activity and pharmacodynamics of new quinolones Eur J Clin Microbiol Infect Dis 22 2003 203 221
12. G.L. Drusano, S.L. Preston, and C. Fowler Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia J Infect Dis 189 2004 1590 1597
13. B.W. Gunderson, G.H. Ross, and K.H. Ibrahim What do we really know about antibiotic pharmacodynamics? Pharmacotherapy 21 2001 302S 318S
14. D.P. Han, S.R. Wisniewski, and L.A. Wilson Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study Am J Ophthalmol 122 1996 1 17
15. D.G. Hwang Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones Surv Ophthalmol 49 Suppl 2 2004 S79 S83
16. M.R. Jacobs, S. Bajaksouzian, and A. Zilles Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. surveillance study Antimicrob Agents Chemother 43 1999 1901 1908
17. G.W. Kaatz, V.V. Moudgal, and S.M. Seo Identification and characterization of a novel efflux-related multidrug resistance phenotype in Staphylococcus aureus J Antimicrob Chemother 50 2002 833 838
18. G. Kahlmeter, D.F. Brown, and F.W. Goldstein European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria J Antimicrob Chemother 52 2003 145 148
19. R. Kishii, M. Takei, and H. Fukuda Contribution of the 8-methoxy group to the activity of gatifloxacin against type II topoisomerases of Streptococcus pneumoniae Antimicrob Agents Chemother 47 2003 77 81
20. R.P. Kowalski, D.K. Dhaliwal, and L.M. Karenchak Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates Am J Ophthalmol 136 2003 500 505
21. P. Liu, M. Müller, and H. Derendorf Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations Int J Antimicrob Agents 19 2002 285 290
22. A.P. MacGowan, and R. Wise Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests J Antimicrob Chemother 48 Suppl 1 2001 S17 S28
23. F.S. Mah Fourth-generation fluoroquinolones: new topical agents in the war on ocular bacterial infections Curr Opin Ophthalmol 15 2004 316 320
24. R. Mather, L.M. Karenchak, and E.G. Romanowski Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics Am J Ophthalmol 133 2002 463 466
25. K. Metzler, G.M. Hansen, and P. Hedlin Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus Int J Antimicrob Agents 24 2004 161 167
26. NCCLS: National Committee for Clinical Laboratory Standards: Performance Standards for Antimicrobial Susceptibility Testing; Twelfth Informational Supplement. Document M100-S12. Wayne, PA, NCCLS, 2002
27. H.C. Neu, and P.D. Ellner The inhibitory quotient Bull N Y Acad Med 59 1983 430 442
28. R.J. Olson Reducing the risk of postoperative endophthalmitis Surv Ophthalmol 49 Suppl 2 2004 S55 S61
29. E. Pestova, J.J. Millichap, and G.A. Noskin Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones J Antimicrob Chemother 45 2000 583 590
30. K.E. Pickerill, J.A. Paladino, and J.J. Schentag Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters Pharmacotherapy 20 2000 417 428
31. L.J.V. Piddock, and Y.F. Jin Antimicrobial activity and accumulation of moxifloxacin in quinolone-susceptible bacteria J Antimicrob Chemother 43 Suppl B 1999 S39 S42
32. S.L. Preston, G.L. Drusano, and A.L. Berman Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials JAMA 279 1998 125 129
33. N. Pushker, T. Dada, and P. Sony Microbial keratitis after laser in situ keratomileusis J Refract Surg 18 2002 280 286
34. M.K. Rhee, R.P. Kowalski, and E.G. Romanowski A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa Am J Ophthalmol 138 2004 226 230
35. S.M. Robertson, M.A. Curtis, and B.A. Schlech Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans Surv Opthalmol 50 Suppl 1 2005 S32 S45
36. J.J. Schentag, K.K. Gilliland, and J.A. Paladino What have we learned from pharmacokinetic and pharmacodynamic theories? Clin Infect Dis 32 Suppl 1 2001 S39 S46
37. H.M. Siefert, A. Domdey-Gette, and K. Henninger Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species J Antimicrob Chemother 43 Suppl B 1999 S69 S76
38. H.M. Siefert, C. Kohlsdorfer, and W. Steinke Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: tissue distribution in male rats J Antimicrob Chemother 43 Suppl B 1999 61 67
39. R. Solomon, E.D. Donnenfeld, and H.D. Perry Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor Opthalmology 112 3 2005 466 469
40. C.J. Soussy, J. Nguyen, and F. Goldstein In vitro antibacterial activity of moxifloxacin against hospital isolates: a multicentre study Clin Microbiol Infect 9 2003 997 1005
41. R. Tipperman Pharmacologic considerations for cataract surgery Curr Opin Ophthalmol 15 2004 51 55
42. Wagner RS, Abelson MB, Shapiro A, Torkildsen G: Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin and levofloxacin concentrations in human conjunctival tissue. Arch Opthalmol 123:1282-3, 2005
43. D.H. Wright, G.H. Brown, and M.L. Peterson Application of fluoroquinolone pharmacodynamics J Antimicrob Chemother 46 2000 669 683
44. G.G. Zhanel, M. Walters, and N. Laing In vitro pharmacodynamic modelling simulating free serum concentrations of fluoroquinolones against multidrug-resistant Streptococcus pneumoniae J Antimicrob Chemother 47 2001 435 440